78 related articles for article (PubMed ID: 24291374)
1. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
[TBL] [Abstract][Full Text] [Related]
2. Serum human epidermal growth factor receptor-2 extracellular domain, carcinoma embryonic antigen and carbohydrate antigen 15-3 combined detection in early diagnosis of breast cancer.
Yuan Q; Song JY; Ye LQ; Zhang YM
J Physiol Pharmacol; 2023 Oct; 74(5):. PubMed ID: 38085516
[TBL] [Abstract][Full Text] [Related]
3. Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer.
Kosaka Y; Minatani N; Tanaka Y; Shida A; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Sato T; Sengoku N; Tanino H; Yamashita K; Watanabe M
Mol Clin Oncol; 2018 Nov; 9(5):566-574. PubMed ID: 30402236
[TBL] [Abstract][Full Text] [Related]
4. Assessment of serum microRNA-21 and miRNA-205 as diagnostic markers for stage I and II breast cancer in Indian population.
Rama K; Bitla AR; Hulikal N; Yootla M; Yadagiri LA; Asha T; Manickavasagam M; Srinivasa Rao P
Indian J Cancer; 2023 Jul; ():. PubMed ID: 38090957
[TBL] [Abstract][Full Text] [Related]
5. Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients.
Fakhari A; Gharepapagh E; Dabiri S; Gilani N
Med J Islam Repub Iran; 2019; 33():142. PubMed ID: 32280648
[No Abstract] [Full Text] [Related]
6. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
7. Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer.
Wu SG; He ZY; Ren HY; Yang LC; Sun JY; Li FY; Guo L; Lin HX
J Cancer; 2016; 7(1):37-41. PubMed ID: 26722358
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
Dis Markers; 2018; 2018():9863092. PubMed ID: 29854028
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
11. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
15. Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer.
Abd ELhafeez AS; Ghanem HM; Swellam M; Taha AM
Cancer Biomark; 2024; 39(4):313-333. PubMed ID: 38250762
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells in peripheral blood as a diagnostic biomarker of breast cancer: A meta-analysis.
Jin T; Chen Y; Chen QY; Xiong Y; Yang JQ
Front Oncol; 2023; 13():1103146. PubMed ID: 37035139
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic role of heart rate variability in breast cancer and its relationship with peripheral serum carcinoembryonic antigen.
Ding L; Yang Y; Chi M; Chen Z; Huang Y; Ouyang W; Li W; He L; Wei T
PLoS One; 2023; 18(4):e0282221. PubMed ID: 37023015
[TBL] [Abstract][Full Text] [Related]
18. The dual-crosslinked prospective values of RAI14 for the diagnosis and chemosurveillance in triple negative breast cancer.
Cui R; Zou J; Zhao Y; Zhao T; Ren L; Li Y
Ann Med; 2023 Dec; 55(1):820-836. PubMed ID: 36880986
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Preoperative Serum Carcinoembryonic Antigen for Overall Survival and Recurrence-Free Survival in Resectable Thymic Epithelial Tumors.
Huang YY; Liu X; Liang SH; Hu Y; Ma GW
Technol Cancer Res Treat; 2022; 21():15330338221119340. PubMed ID: 36217838
[No Abstract] [Full Text] [Related]
20. The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin.
Yamamoto S; Adachi S; Wada T; Narui K; Kimura A; Oshi M; Yamada A; Misumi T; Endo I
In Vivo; 2022; 36(4):1854-1859. PubMed ID: 35738631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
